| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
The primary target of sucrose-epichlorohydrin copolymer is not a specific biological receptor but rather the cellular environment. It works as a macromolecular crowding reagent to promote protein liquid-liquid phase separation (LLPS). By creating a crowded environment, it influences protein-protein interactions, protein folding, and biomolecular condensation. The compound's porous structure and high surface area make it ideal for cell separation and isolation processes. It cannot penetrate cell membranes, making it suitable for density gradient centrifugation and other cell separation techniques.
|
|---|---|
| ln Vitro |
In vitro, sucrose-epichlorohydrin copolymer is used as a macromolecular crowding reagent to promote protein phase separation. It is primarily utilized in biological and biochemical applications, particularly in cell separation and isolation processes. The compound's porous structure and high surface area make it ideal for these applications. It is used in density gradient centrifugation for the separation of cells, subcellular organelles, and other biological particles. The compound cannot penetrate cell membranes, making it suitable for these applications.
|
| ln Vivo |
In vivo data for sucrose-epichlorohydrin copolymer is limited, as it is primarily used as a research reagent for in vitro applications. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Its primary applications are in cell separation and protein phase separation studies. The compound's large molecular weight (3×10⁵ to 5×10⁵ for Polysucrose 400) and inability to penetrate cell membranes limit its in vivo applications. Specific in vivo data is not available in the public literature.
|
| Enzyme Assay |
In vitro assays for sucrose-epichlorohydrin copolymer typically evaluate its effectiveness as a macromolecular crowding reagent or as a density gradient medium. A standard protocol for cell separation involves preparing a density gradient using the compound dissolved in buffer. Cells or biological particles are layered on top of the gradient and centrifuged. Different cell types or particles separate based on their density. For protein phase separation studies, the compound is added to protein solutions at varying concentrations. Protein condensation is assessed by turbidity measurements, microscopy, or other methods. The compound's effectiveness is evaluated based on separation efficiency or phase separation induction.
|
| Cell Assay |
Cellular assays for sucrose-epichlorohydrin copolymer typically involve cell separation and isolation. A standard protocol involves preparing a density gradient using the compound in appropriate buffer. Cells are layered on top of the gradient and centrifuged at specific speeds for defined durations. Different cell populations are collected from different density layers. Cell viability and purity are assessed using trypan blue exclusion, flow cytometry, or other methods. The compound's effectiveness is evaluated based on cell recovery and purity.
|
| Animal Protocol |
In vivo animal studies for sucrose-epichlorohydrin copolymer are not standard, as it is primarily used as an in vitro research reagent. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Any animal studies would be limited to evaluating the compound's effects as a macromolecular crowding agent or its pharmacokinetics. The compound's large molecular weight and inability to penetrate cell membranes limit its in vivo applications. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for sucrose-epichlorohydrin copolymer is limited, as it is primarily used as an in vitro research reagent. The compound has a molecular weight range of 3×10⁵ to 5×10⁵ for Polysucrose 400 and 6×10⁴ to 8×10⁴ for Polysucrose 70. It is a solid at room temperature and is soluble in water. The compound cannot penetrate cell membranes. As a large polymer, it is not expected to be absorbed systemically. Specific ADME data is not available.
|
| Toxicity/Toxicokinetics |
The sucrose-epichlorohydrin copolymer is generally considered safe for research use. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed.
|
| References |
[1]. Simon Alberti, et al. Considerations and Challenges in Studying Liquid-Liquid Phase Separation and Biomolecular Condensates. Cell. 2019 Jan 24;176(3):419-434.
|
| Additional Infomation |
The sucrose-epichlorohydrin copolymer (Polysucrose 400, Ficoll, CAS 26873-85-8) is a biochemical reagent and polymer used in life science research. It is a nonionic synthetic copolymer derived from sucrose and epichlorohydrin. It works as a macromolecular crowding reagent to promote protein phase separation and is used in cell separation and isolation processes. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers.
|
| Molecular Formula |
200-334-9
|
|---|---|
| Molecular Weight |
号MFCD00081599
|
| Exact Mass |
434.119
|
| CAS # |
26873-85-8
|
| Related CAS # |
26873-85-8
|
| PubChem CID |
88330506
|
| Appearance |
Colorless to light yellow solid powder
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
433
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C1C(O1)CCl.C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO)O)O)O)O
|
| InChi Key |
IACFXVUNKCXYJM-AKSHDPDZSA-N
|
| InChi Code |
InChI=1S/C12H22O11.C3H5ClO/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12;4-1-3-2-5-3/h4-11,13-20H,1-3H2;3H,1-2H2/t4-,5-,6-,7-,8+,9-,10+,11-,12+;/m1./s1
|
| Chemical Name |
2-(chloromethyl)oxirane;(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
